Medicines planning
47 results
Applied filters
The licence and supporting evidence for golimumab biosimilar
2 June 2026We highlight evidence for licensed golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
Marketed CAR-T therapy
13 February 2026This document outlines key areas where Chief Pharmacists should focus pharmaceutical expertise prior to an organisation implementing CAR-T therapy.
Annual medicines planning publication, Prescribing Outlook
12 January 2026Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.
Using our annual medicines planning publication, Prescribing Outlook
28 October 2024Users should be aware of the constraints and assumptions in creating Prescribing Outlook, as well as their responsibilities for use.
Annual medicines planning
Our annual Prescribing Outlook outputs support planning, implementation and budget planning for medicines every year.
The licence and supporting evidence for tocilizumab biosimilar
6 March 2026Two licensed tocilizumab biosimilars are available: Tyenne and Avtozma. Learn about the licensed indications, supporting evidence and key differences.
Preparing to use tocilizumab biosimilar
6 March 2026Two tocilizumab biosimilars are now available. We offer general information and implementation advice.
Understanding data exclusivity and market protection
11 July 2025Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.
Preparing to use aflibercept 2mg biosimilar
3 February 2026Aflibercept 2mg biosimilars for use in ophthalmology are available for NHS use. We offer general information and implementation advice.
Understanding biosimilar and generic market entry
12 September 2025New medicines have several protections against competition. Other factors influence availability of biosimilars or generics after loss of exclusivity.